

Europe Gastric Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Market Report | 2023-02-01 | 262 pages | Data Bridge Market Research

AVAILABLE LICENSES:

- Single User License \$3500.00
- Corporate Users License \$4200.00

Report description:

Europe gastric cancer diagnostics market is projected to register a CAGR of 8.1% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

Europe Gastric Cancer Diagnostics Market, By Product Type (Instruments, Reagents & Consumables, Services), Diagnostics Type (Gastric (Pre) Cancer Screening Tests/Physical Exam, Confirmatory Tests), Age Group (Adult, Pediatric, and Geriatrics), Type (Intestinal Or Diffuse Adenocarcinoma, Carcinoid Tumor, Gastrointestinal Stromal Tumor (GIST), Gastric Lymphoma and Others), Stage (Stage 0, Stage I, Stage II, Stage III), Gender (Male and Female), Sample Type (Blood, Tissue, Urine, and Stool), End Users (Diagnostic Laboratories, Hospitals, Cancer Research Institutes, Oncology Specialty Clinics, and Others), Distribution Channel (Direct Tenders and Retail Sales), Country (Germany, France, Spain, Italy, Netherlands, Switzerland, Russia, Belgium, Turkey, Ireland, Rest Of Europe) Industry Trends and Forecast To 2030

Some of the major factors contributing to the growth of the gastric cancer diagnostics market are:

- Rising healthcare expenditure for better health services
- Growing demand for better quality healthcare
- Increase in diagnostic procedures for gastric cancer

Market Players:

Some of the key market players in Europe gastric cancer diagnostics market are listed below:

- BIOMERIEUX
- Myriad Genetics, Inc.
- Vela Diagnostics
- Abbott
- Fujirebio (An H.U. Group company)
- Thermo Fisher Scientific Inc.
- F. Hoffmann-La Roche Ltd

Scotts International, EU Vat number: PL 6772247784

- GENERAL ELECTRIC COMPANY
- Agilent Technologies, Inc.
- Biohit Oyj
- FOUNDATION MEDICINE, INC.
- DiaSorin S.p.A
- Paragon Genomics, Inc.
- QIAGEN

Table of Contents:

TABLE OF CONTENTS

- 1 INTRODUCTION 47
- 1.1 OBJECTIVES OF THE STUDY 47
- 1.2 MARKET DEFINITION 47
- 1.3 OVERVIEW OF THE EUROPE GASTRIC CANCER DIAGNOSTICS MARKET 47
- 1.4 LIMITATIONS 50
- 1.5 MARKETS COVERED 50
- 2 MARKET SEGMENTATION 53
- 2.1 MARKETS COVERED 53
- 2.2 GEOGRAPHICAL SCOPE 54
- 2.3 YEARS CONSIDERED FOR THE STUDY 55
- 2.4 CURRENCY AND PRICING 55
- 2.5 DBMR TRIPOD DATA VALIDATION MODEL 56
- 2.6 MULTIVARIATE MODELLING 59
- 2.7 PRODUCT TYPE LIFELINE CURVE 59
- 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 60
- 2.9 DBMR MARKET POSITION GRID 61
- 2.10 VENDOR SHARE ANALYSIS 62
- 2.11 MARKET END COVERAGE GRID 63
- 2.12 SECONDARY SOURCES 64
- 2.13 ASSUMPTIONS 64
- 3 EXECUTIVE SUMMARY 65
- 4 PREMIUM INSIGHT 68
- 4.1 PESTEL'S MODEL 69
- 4.2 PORTER'S 5 FORCES 70
- 4.3 EPIDEMIOLOGY 71
- 4.4 BRAND ANALYSIS 72
- 4.5 ROLE OF ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING (ML): EUROPE GASTRIC CANCER DIAGNOSTICS MARKET 76
- 4.6 INDUSTRY INSIGHTS: 78
- 5 EUROPE GASTRIC CANCER DIAGNOSTICS MARKET, REGULATORY 79
- 5.1 EUROPEAN UNION (EU)- 79
- 6 MARKET OVERVIEW 81
- **6.1 DRIVERS 83**
- 6.1.1 INCREASE IN INCIDENCE OF GASTROINTESTINAL TUMOURS, LYMPHOMA, AND ADENOCARCINOMA 83
- 6.1.2 RISE IN ALCOHOL CONSUMPTION AND SURGE IN SMOKING 83

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.1.3 INCREASE IN THE GERIATRIC POPULATION 84
- 6.1.4 RECENT ADVANCEMENTS IN GASTRIC CANCER DIAGNOSTICS PRODUCTS 84
- 6.2 RESTRAINTS 85
- 6.2.1 HIGH COST OF GASTRIC CANCER DIAGNOSTIC TEST 85
- 6.2.2 LACK OF SUFFICIENT FINANCIAL SUPPORT FROM HEALTH INSURANCE POLICIES 85
- 6.3 OPPORTUNITIES 86
- 6.3.1 RISE IN THE ADOPTION OF AUTOMATED SYSTEMS 86
- 6.3.2 INCREASED RESEARCH AND DEVELOPMENT ON CANCER DIAGNOSTICS PRODUCTS 86
- 6.3.3 STRATEGIC INITIATIVES BY EMERGING PLAYERS 87
- 6.4 CHALLENGES 88
- 6.4.1 STRINGENT REGULATIONS AND POLICIES FOR APPROVING THE COMPLICATED NATURE OF RADIATION DEVICES 88
- 6.4.2 LIMITATIONS OF RADIATION TESTS 88
- 7 EUROPE GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 89
- 7.1 OVERVIEW 90
- 7.2 REAGENTS & CONSUMABLES 93
- 7.2.1 KITS 94
- 7.2.1.1 DNA POLYMERASE KITS 94
- 7.2.1.2 PCR KITS 94
- 7.2.1.3 NUCLEIC ACID ISOLATION KITS 94
- 7.2.1.4 OTHERS 94
- 7.2.2 REAGENTS 95
- 7.2.2.1 ASSAYS 95
- 7.2.2.2 BUFFERS 95
- 7.2.2.3 PRIMERS 95
- 7.2.2.4 OTHERS 95
- 7.3 INSTRUMENTS 96
- 7.4 SERVICES 97
- 8 EUROPE GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE 98
- 8.1 OVERVIEW 99
- 8.2 CONFIRMATORY TEST 102
- 8.2.1 IMAGING TESTS 103
- 8.2.1.1 PET SCAN/CT SCAN 103
- 8.2.1.2 CT SCAN 103
- 8.2.1.3 ULTRASOUND 103
- 8.2.1.4 MRI 104
- 8.2.1.5 X-RAY 104
- 8.2.2 BIOMARKER 104
- 8.2.2.1 DNA BIOMARKER 104
- 8.2.2.2 RNA BIOMARKER 104
- 8.2.2.3 PROTEIN BIOMARKER 104
- 8.2.3 BIOPSY 104
- 8.3 GASTRIC CANCER SCREENING TESTS/PHYSICAL EXAM 105
- 9 EUROPE GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP 106
- 9.1 OVERVIEW 107
- 9.2 GERIATRICS 110
- 9.3 ADULT 111
- 9.4 PEDIATRIC 112

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10 EUROPE GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE 113
- 10.1 OVERVIEW 114
- 10.2 INTESTINAL OR DIFFUSE ADENOCARCINOMA 117
- 10.3 CARCINOID TUMOR 118
- 10.4 GASTROINTESTINAL STROMAL TUMOR 119
- 10.5 GASTRIC LYMPHOMA 120
- 10.6 OTHERS 121
- 11 EUROPE GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE 122
- 11.1 OVERVIEW 123
- 11.2 STAGE I 126
- 11.2.1 STAGE IA 127
- 11.2.2 STAGE IB 127
- 11.3 STAGE II 127
- 11.3.1 STAGE IIA 128
- 11.3.2 STAGE IIB 128
- 11.4 STAGE III 128
- 11.4.1 STAGE IIIA 129
- 11.4.2 STAGE IIIB 130
- 11.4.3 STAGE IIIC 130
- 11.5 STAGE 0 130
- 12 EUROPE GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER 131
- 12.1 OVERVIEW 132
- 12.2 MALE 135
- 12.3 FEMALE 136
- 13 EUROPE GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE 137
- 13.1 OVERVIEW 138
- 13.2 STOOL 141
- 13.3 TISSUE 142
- 13.4 BLOOD 143
- 13.5 URINE 144
- 14 EUROPE GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER 145
- 14.1 OVERVIEW 146
- 14.2 HOSPITALS 149
- 14.3 DIAGNOSTIC LABORATORIES 150
- 14.4 CANCER RESEARCH INSTITUTES 151
- 14.5 ONCOLOGY SPECIALTY CLINICS 152
- 14.6 OTHERS 153
- 15 EUROPE GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 154
- 15.1 OVERVIEW 155
- 15.2 DIRECT TENDERS 158
- 15.3 RETAIL SALES 159
- 16 EUROPE GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION 160
- 16.1 EUROPE 161
- 16.1.1 GERMANY 172
- 16.1.2 FRANCE 177
- 16.1.3 U.K 182
- 16.1.4 RUSSIA 187

- 16.1.5 ITALY 192
- 16.1.6 SPAIN 197
- 16.1.7 BELGIUM 202
- 16.1.8 NETHERLANDS 207
- 16.1.9 TURKEY 212
- 16.1.10 SWITZERLAND 217
- 16.1.11 REST OF EUROPE 222
- 17 EUROPE GASTRIC CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 223
- 17.1 COMPANY SHARE ANALYSIS: EUROPE 223
- 18 SWOT ANALYSIS 224
- 19 COMPANY PROFILE 225
- 19.1 F. HOFFMANN-LA ROCHE LTD 225
- 19.1.1 COMPANY SNAPSHOT 225
- 19.1.2 REVENUE ANALYSIS 225
- 19.1.3 COMPANY SHARE ANALYSIS 226
- 19.1.4 PRODUCT PORTFOLIO 226
- 19.1.5 RECENT DEVELOPMENT 226
- 19.2 GENERAL ELECTRIC 227
- 19.2.1 COMPANY SNAPSHOT 227
- 19.2.2 REVENUE ANALYSIS 227
- 19.2.3 COMPANY SHARE ANALYSIS 228
- 19.2.4 PRODUCT PORTFOLIO 228
- 19.2.5 RECENT DEVELOPMENT 228
- 19.3 ABBOTT 229
- 19.3.1 COMPANY SNAPSHOT 229
- 19.3.2 REVENUE ANALYSIS 229
- 19.3.3 COMPANY SHARE ANALYSIS 230
- 19.3.4 PRODUCT PORTFOLIO 230
- 19.3.5 RECENT DEVELOPMENT 230
- 19.4 OIAGEN 231
- 19.4.1 COMPANY SNAPSHOT 231
- 19.4.2 REVENUE ANALYSIS 231
- 19.4.3 COMPANY SHARE ANALYSIS 232
- 19.4.4 PRODUCT PORTFOLIO 232
- 19.4.5 RECENT DEVELOPMENT 232
- 19.5 MYRIAD GENETICS, INC. 233
- 19.5.1 COMPANY SNAPSHOT 233
- 19.5.2 REVENUE ANALYSIS 233
- 19.5.3 COMPANY SHARE ANALYSIS 234
- 19.5.4 PRODUCT PORTFOLIO 234
- 19.5.5 RECENT DEVELOPMENT 234
- 19.6 ACON LABORATORIES, INC. 235
- 19.6.1 COMPANY SNAPSHOT 235
- 19.6.2 PRODUCT PORTFOLIO 235
- 19.6.3 RECENT DEVELOPMENT 235
- 19.7 ADVACARE PHARMA 236
- 19.7.1 COMPANY SNAPSHOT 236

- 19.7.2 PRODUCT PORTFOLIO 236
- 19.7.3 RECENT DEVELOPMENT 236
- 19.8 AGILENT TECHNOLOGIES, INC. 237
- 19.8.1 COMPANY SNAPSHOT 237
- 19.8.2 REVENUE ANALYSIS 237
- 19.8.3 PRODUCT PORTFOLIO 238
- 19.8.4 RECENT DEVELOPMENTS 238
- 19.9 BIOMERIEUX 239
- 19.9.1 COMPANY SNAPSHOT 239
- 19.9.2 REVENUE ANALYSIS 239
- 19.9.3 PRODUCT PORTFOLIO 240
- 19.9.4 RECENT DEVELOPMENT 240
- 19.10 BIOCEPT, INC. 241
- 19.10.1 COMPANY SNAPSHOT 241
- 19.10.2 REVENUE ANALYSIS 241
- 19.10.3 PRODUCT PORTFOLIO 242
- 19.10.4 RECENT DEVELOPMENT 242
- 19.11 BIOHIT OYJ 243
- 19.11.1 COMPANY SNAPSHOT 243
- 19.11.2 REVENUE ANALYSIS 243
- 19.11.3 PRODUCT PORTFOLIO 244
- 19.11.4 RECENT DEVELOPMENT 244
- 19.12 DIASORIN S.P.A 245
- 19.12.1 COMPANY SNAPSHOT 245
- 19.12.2 REVENUE ANALYSIS 245
- 19.12.3 PRODUCT PORTFOLIO 246
- 19.12.4 RECENT DEVELOPMENT 246
- 19.13 ENDOFOTONICS PTE LTD 247
- 19.13.1 COMPANY SNAPSHOT 247
- 19.13.2 PRODUCT PORTFOLIO 247
- 19.13.3 RECENT DEVELOPMENT 247
- 19.14 FOUNDATION MEDICINE, INC. 248
- 19.14.1 COMPANY SNAPSHOT 248
- 19.14.2 PRODUCT PORTFOLIO 248
- 19.14.3 RECENT DEVELOPMENTS 248
- 19.15 FUJIREBIO (AN H.U. GROUP COMPANY) 249
- 19.15.1 COMPANY SNAPSHOT 249
- 19.15.2 REVENUE ANALYSIS 249
- 19.15.3 PRODUCT PORTFOLIO 250
- 19.15.4 RECENT DEVELOPMENT 250
- 19.16 MIRXES PTE LTD. 251
- 19.16.1 COMPANY SNAPSHOT 251
- 19.16.2 PRODUCT PORTFOLIO 251
- 19.16.3 RECENT DEVELOPMENT 251
- 19.17 PARAGON GENOMICS, INC. 252
- 19.17.1 COMPANY SNAPSHOT 252
- 19.17.2 PRODUCT PORTFOLIO 252

19.17.3 RECENT DEVELOPMENTS 252

19.18 TECO DIAGNOSTICS 253

19.18.1 COMPANY SNAPSHOT 253

19.18.2 PRODUCT PORTFOLIO 253

19.18.3 RECENT DEVELOPMENT 253

19.19 THERMO FISHER SCIENTIFIC INC. 254

19.19.1 COMPANY SNAPSHOT 254

19.19.2 REVENUE ANALYSIS 254

19.19.3 PRODUCT PORTFOLIO 255

19.19.4 RECENT DEVELOPMENTS 255

19.20 VELA DIAGNOSTICS 256

19.20.1 COMPANY SNAPSHOT 256

19.20.2 PRODUCT PORTFOLIO 256

19.20.3 RECENT DEVELOPMENTS 256

20 QUESTIONNAIRE 257

21 RELATED REPORTS 262



Print this form

To place an Order with Scotts International:

 $\hfill \Box$ - Complete the relevant blank fields and sign

Europe Gastric Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Market Report | 2023-02-01 | 262 pages | Data Bridge Market Research

Send as a scann	ed email to support@scotts-interna	ational.com		
ORDER FORM:				
Select license	License			Price
	Single User License			\$3500.00
	Corporate Users License			\$4200.00
			VAT	
			Total	
*Please circle the releva	ant license option. For any questions pla	ease contact support@sc	otts-international.com or 0048 603 3	94 346.
** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Number				
_				
Email*		Phone*		
First Name*		Last Name*		
Job title*				
Company Name*		EU Vat / Tax ID / NIP number*		
Address*		City*		
Zip Code*		Country*		
		Date	2025-05-13	
		Signature		
		j		